KZR-261 in Subjects With Advanced Solid Malignancies
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
A first-in-human, open-label, multicenter, Phase 1 study of KZR-261 designed to assess the
safety and tolerability, preliminary anti-tumor activity, and pharmacokinetics (PK) of
KZR-261, as well as identify the recommended Phase 2 dose (RP2D). The study comprises a Part
1 (Dose Escalation) and a Part 2 (Dose Expansion) in solid organ tumors (melanoma/uveal
melanoma, mesothelioma, colorectal cancer, prostate cancer, and "all-tumors").